Abstract
Background Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics are at high risk for vaccine preventable infections. Their ability to mount adequate vaccine responses is unclear.
Aim to assess immune responses to mRNA-COVID-19 vaccine, and safety profile, in patients with IBD stratified according to therapy, compared to healthy controls (HC).
Methods Prospective, controlled, multi-center Israeli study. Subjects enrolled received two BNT162b2 (Pfizer/BioNTech) doses. Anti-spike (S) antibodies levels and functional activity, anti-TNFα levels and adverse events (AEs) were detected longitudinaly.
Results Overall 258 subjects: 185 IBD (67 treated with anti-TNFα), and 73 HC. After the first vaccine dose all HC were seropositive, while some patients with IBD, regardless of treatment, remained seronegative. After the second dose all subjects were seropositive, however anti-S levels were significantly lower in anti-TNFα treated compared to untreated patients, and HC (p<0.001; p<0.001, respectively). Neutralizing and inhibitory functions were both lower in anti-TNFα treated compared to untreated patients, and HC (p<0.03; p<0.0001, respectively). Anti-TNFα drug levels and vaccine responses did not affect anti-S levels. Infection rate (∼2%) and AEs were comparable in all groups. IBD activity did not change in response to BNT162b2.
Conclusions In this prospective study in patients with IBD stratified according to treatment all patients mounted an immune response to two doses of BNT162b2. However, its magnitude was significantly lower in patients treated with anti-TNFα, regardless of administration timing and drug levels. Vaccine was safe. As vaccine immune response longevity in this group may be limited, vaccine booster dose should be considered.
Competing Interest Statement
ID: Consultation/advisory board: Abbvie, Athos, Arena, Cambridge Healthcare, Celltrion, Celgene/BMS, DSM, Ferring, Food Industries Organization, Iterative Scopes, Integra Holdings, Janssen, MSD, Neopharm, Pfizer, Rafa laboratories, Roche/Genentech, Sangamo, Sublimity, Takeda, Wildbio Speaking/teaching: Abbvie, Altman, Celltrion, Celgene/BMS, Ferring, Falk Pharma, Janssen, MSD, Neopharm, Nestle, Pfizer, Rafa laboratories, Roche/Genentech, Sandoz, Takeda ABGS: Grant support from Takeda and Janssen, consultancy and lectures fees from Takeda, Janssen, Abbvie, Pfizer, Neopharm and BMS. EZ: has received research support and consulting fees from Janssen, Abbvie, Takeda, Neopharm, Celgene and Pfizer. All other authors declare they have no conflict of interest.
Clinical Trial
Our trial is not a clinical trial per se. It is a non interventional, observational trial
Funding Statement
The study was partially supported by a generous grant from The Leona M. and Harry B. Helmsley Charitable Trust. The Crohn's and Colitis Foundation of Israel, the European Federation of Crohn's and Colitis Associations and the AMICI group are thanked for partially funding the study and supporting recruitment efforts. NTF acknowledges the kind support of L. Cohen and the Milner Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Rabin Medical Center IRB. Jabotinski 39, Petah Tikva, Israel. IRB approval no.1072-20
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
no data available
- List of abbreviations
- 5-ASA
- 5-aminosalicylic acid
- Ab
- antibodies
- ACE2
- angiotensin converting enzyme2
- ADA
- adalimumab
- AEs
- adverse events
- Anti-TNFα
- anti-tumor necrosis factor (TNF) α
- AU
- activity units
- BMI
- body mass index
- CI
- confidence intervals
- COVID-19
- Corona Virus 2019
- CRP
- C-reactive protein
- GMC
- as geometric mean concentration
- HBI
- Harvey-Bradshaw Index
- HC
- healthy controls
- HEK
- human embryonic kidney
- IBD-U
- IBD-Unclassified
- IFX
- infliximab
- IPAA
- ileal pouch anal-anastomosis
- IQR
- Interquartile range
- N
- nucleocapsid
- PDAI
- Pouch Disease Activity Index
- RBD
- Receptor binding domain
- S
- spike
- SAEs
- severe adverse events
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- SCCAI
- Simple Clinical Colitis Activity Index
- VSV
- vesicular stomatitis virus
